Skip to main content
. 2022 May 23;19:88. doi: 10.1186/s12985-022-01823-0

Table 2.

Cell viabilities from MTT assay in combined treatments compared to H1N1

Compound Cell viability (mean ± SD)
Co-pen Pre-pen Post-pen
Ascorbate + H1N1 2.97 ± 0.01** 1.82 ± 0.79** 3.69 ± 0.21**
Acetate + H1N1 1.11 ± 0.02** 1.08 ± 0.02** 0.82 ± 0.09**
Citrate + H1N1 1.34 ± 0.41** 1.03 ± 0.04** 0.92 ± 0.03**
Amantadine hydrochloride + H1N1 0.89 ± 0.03** 0.52 ± 0.04* 0.54 ± 0.05*
Oseltamivir carboxylate + H1N1 0.98 ± 0.00** 0.93 ± 0.00** 0.92 ± 0.03**
H1N1 0.23 ± 0.04 0.23 ± 0.04 0.23 ± 0.04

Data presented as mean ± SD are averages of 4 independent MTT assays

*Significantly and** highly significantly different from untreated sample (P ≤ 0.05 and P ≤ 0.01) were analyzed by SPSS, Tukey post-hoc test